Burkitt lymphoma (BL) is an aggressive form of B cell lymphoma that can affect children and
adults. The study of BL led to the identification of the first recurrent chromosomal aberration …

Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving
survival and reducing long-term side-effects for children and adolescents with cancer. The …

Background Rituximab added to chemotherapy prolongs survival among adults with B-cell
cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non …

While survival has improved for Burkitt lymphoma patients, potential differences in outcome
between pediatric and adult patients remain unclear. In both age groups, survival remains …

Abstract The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums
focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is …

Despite improved outcomes achieved in the last decades for children with newly diagnosed
leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a …

The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen
receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T …

Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-
line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug …

Abstract The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE
and the European Medicines Agency focused on immune checkpoint inhibitors for use in …

Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival,
however, current clinical risk stratification places as many as half of patients in a high-risk …